The Ren Lab
To study tumor microenvironment and tumor immunology in cancer therapeutic resistance and metastatic relapse
Principal Investigator
Location
Connect
Topics
OUR RESEARCH FOCUS
The Ren group mainly focuses on elucidating how mesenchymal lineage cells (mesenchymal stem cells and fibroblasts) and immune-regulatory myeloid cells (neutrophils and macrophages) modulate the adaptive immune responses in cancer treatment resistance and metastatic relapse. These studies will fully take advantage of the unique research platform--patient-derived xenograft (PDX) tumors in humanized mouse models at The Jackson Laboratory, with the research goal to develop novel strategies targeting tumor microenvironment to improve the efficacies of conventional cancer therapies and new therapeutics such as immunotherapy.
-
Research HighlightNovember 28, 2023Focusing on mitochondria
A. Phillip West, Ph.D., investigates mitochondria, with a focus on their roles in immunity and contributions to disease. -
Research HighlightNovember 07, 2023Uniting the worlds of biomedical engineering, immunology, and microbiology
Assistant Professor Sasan Jalili unites the worlds of biomedical engineering, immunology, and microbiology, offering fresh insights into the intricate interactions between the human immune system and microbiome. -
Research HighlightOctober 20, 2023Exposing a master regulator of cancer treatment induced ovarian failure
New findings into a master regulator of cancer treatment–induced ovarian failure and infertility have opened up potential therapeutic avenues for treatments to preserve a woman’s long-term ovarian function. -
Research HighlightSeptember 25, 2023Immunometabolism research unearths a potential treatment for lupus
Chih-Hao “Lucas” Chang's immune system and metabolism research have led him to a prospective treatment option for the autoimmune disease systemic lupus erythematosus (SLE or lupus).
-
Featured ArticleNovember 07, 2023The state of biomedicine presented at the Biomedical Innovation and Technology Conference
The current state of biomedicine and its potential for the future in Maine and beyond as presented in the inaugural Biomedical Innovation and Technology (BIT) Conference. -
Research HighlightOctober 23, 2023Examining the nongenetic drivers of acute leukemia drug resistance
Research from Eric Wang examines how nongenetic mechanisms of cancer development may represent therapeutic vulnerabilities that can be exploited to overcome drug resistance in acute myeloid leukemia and acute lymphoblastic leukemia. -
Featured ArticleOctober 17, 2023New virtual series, "Scientifically Speaking," features postdoctoral associates
JAX has kicked off "Scientifically Speaking," a new twice-yearly virtual event featuring JAX leaders and scientists striving to change the future of human health. -
Featured ArticleSeptember 11, 2023Personalizing pediatric cancer research
Professor Ching Lau envisions a world where his pediatric cancer patients receive targeted medicines with minimal side effects.